Interpace Biosciences Uplisting: Thyroid Testing Growth Meets a Tight Float
Interpace Biosciences, Inc. (NASDAQ: IDXG) is expected to list on 2026-10-21, with a $6.00-$7.00 price range and 3.1 million shares offered. The company is already public on OTC-style markets, so this is an uplisting and offering rather than a classic first-time IPO. Bull case: a profitable thyroid diagnostics niche with growing revenue; bear case: customer concentration and reimbursement risk still matter.
Interpace Biosciences, Inc. (NASDAQ: IDXG) is expected to list on 2026-10-21, with a $6.00-$7.00 price range and 3.1 million shares offered. The company is already public on OTC-style markets, so this is an uplisting and offering rather than a classic first-time IPO. Bull case: a profitable thyroid diagnostics niche with growing revenue; bear case: customer concentration and reimbursement risk still matter.
Quick Facts
Expected listing date: October 21, 2026
Exchange: NASDAQ
Proposed symbol: IDXG
Status: Expected
Company Overview
Interpace Biosciences is a molecular diagnostics company focused on cancer risk stratification, especially thyroid and endocrine cancer. Its core commercial platform combines ThyGeNEXT, a DNA/RNA sequencing oncogene and mRNA fusion panel, with ThyraMIRv2, a microRNA-based endocrine cancer diagnostic test. The company says these tests help physicians decide whether indeterminate thyroid nodules are likely malignant and whether surgery or surveillance is the better path. Its customers are primarily physicians, hospitals, clinics, and in some cases commercial labs and pathology groups.
The company is headquartered in Parsippany, New Jersey. In the S-1, Interpace says its thyroid assay business has grown from $20.3 million in 2022 to $34.8 million in 2025, and it estimates its share of the U.S. thyroid assay market at about 20%. The broader market it is targeting is not huge, but it is attractive: the company pegs the U.S. endocrine/thyroid cancer assay market at about $300 million annually, with roughly 525,000 to 600,000 thyroid FNA procedures each year and 20% to 30% of those cases falling into the indeterminate bucket. That creates a clear use case for molecular testing, but it also means competition is intense and reimbursement matters a lot.
Why They're Going Public
Interpace says it expects net proceeds of about $17.9 million, or $20.8 million if the underwriter’s over-allotment option is fully exercised. The company plans to use the money for working capital, capital expenditures, and general corporate purposes.
It also wants flexibility to develop a new test for pancreatic cyst and Barrett’s esophagus progression to cancer, and it may use proceeds to in-license, acquire, or invest in complementary businesses, technologies, products, or assets. In practical terms, the offering gives the company more balance-sheet room to support its core thyroid franchise while funding adjacent diagnostics opportunities.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The thyroid-only business has shown steady top-line expansion in the S-1: revenue was $20.3 million in 2022, $26.6 million in 2023, $31.0 million in 2024, and $34.8 million in 2025. That works out to about 31% growth in 2023, 16.5% in 2024, and 12.3% in 2025, with the company citing a 19.7% CAGR from 2022 to 2025 for ThyGeNEXT plus ThyraMIRv2. For full-year 2025, the company reported revenue, net of $38.728 million versus $46.926 million in 2024, reflecting a decline of about 17.5% on the broader company reporting basis.
Profitability is mixed but better than many diagnostics names at this stage. Interpace reported gross profit of $24.130 million on $38.728 million of revenue in 2025, implying a gross margin of about 62.3%. It also reported net income of $24.575 million in 2025 versus $6.702 million in 2024, but management said that result was heavily affected by a one-time, non-cash tax-related accounting adjustment tied to releasing a deferred tax valuation allowance. Operating income was $4.084 million in 2025 versus $8.108 million in 2024. On the balance sheet, cash and cash equivalents were $2.688 million as of June 30, 2026, and $2.505 million at December 31, 2025, up from $1.461 million at December 31, 2024.
Risk Factors
The biggest risk is that this is still a reimbursement-driven diagnostics business. Interpace depends on sales and reimbursements from clinical services, and the company says revenue recognition relies on estimates for future collections. If payer behavior shifts, reimbursement gets disrupted, or collection assumptions prove too optimistic, results can move quickly. The company also notes prior operating losses and says future revenue, net income, and EBITDA estimates may not come in as expected.
Customer concentration and competition also matter. LabCorp was the company’s largest customer in 2025 and the first half of 2026 for ThyGeNEXT/ThyraMIRv2, so any change in that relationship would be meaningful. The company says its two largest competitors have estimated market shares of 45% and 30%, versus its own 20% share, and it faces competition from large diagnostic labs and molecular testing companies. Investors should also watch dilution and supply overhang: the company is offering 3,100,000 shares, the largest holders are subject to 90-day lockups, and the deal is being used to strengthen the balance sheet rather than to fund a transformational expansion.
Comparable Public Companies
Closest public comps in molecular and specialty diagnostics include Veracyte (VCYT), Exact Sciences (EXAS), Natera (NTRA), NeoGenomics (NEO), and Guardant Health (GH). Interpace is much smaller than the better-known names in that group, and its story is more concentrated around a single diagnostic workflow rather than a broad multi-assay platform. That makes the comparison useful for market context, but not for direct scale matching.
On valuation, this peer set is usually discussed on price-to-sales or enterprise value-to-revenue rather than earnings multiples, since several names are not consistently profitable. The company materials reviewed did not include a clean current comp table, so exact multiples are not being inferred here. Broadly, the diagnostics group has been a mixed trading environment rather than a uniformly hot one: some names have benefited from renewed interest in profitable growth, while others have remained range-bound as investors focus on reimbursement, growth durability, and cash burn. For Interpace, that means the market will likely judge the deal on whether the thyroid franchise can keep compounding while the company uses the offering to extend its runway.
Verdict
The key thing to watch as Interpace prices is whether investors are comfortable paying up for a small, focused diagnostics business with real revenue traction but a narrow customer base and reimbursement exposure. The setup favors a story built around a profitable niche, a 20% share in a roughly $300 million market, and a platform the company says has 99% NPV and 94% PPV at 30% disease prevalence. But the offering is also coming from a company that is already public, so the market will likely focus less on novelty and more on execution, customer concentration, and whether the cash raise meaningfully improves flexibility.
The timing angle is straightforward: this is not a first-time IPO, but an uplisting and capital-markets reset for a diagnostics name trying to move into a more visible venue. That matters because the sector narrative is still centered on secular demand for molecular testing, especially where diagnostics can reduce unnecessary surgery and improve risk stratification. If the pricing lands near the midpoint of the $6.00-$7.00 range, shareholders should watch whether the market treats Interpace as a credible growth-and-profitability story or as a thinly traded niche name with limited room for error.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.